Skip to content
Open in App
Exelixis logo

Exelixis

web2

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercializati...

Symbol · EXEL
Company profile

About

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

People

Company team

MC

Mary C. Beckerle

Independent Director

Company leadership profile.

RM

Ronald M. Evans

Member of the Scientific Advisory Board

Company leadership profile.

SG

Sue Gail Eckhardt

Independent Director

Company leadership profile.

CL

Charles L. Sawyers

Member of the Scientific Advisory Board

Company leadership profile.

MC

Maria C. Freire

Independent Director

Company leadership profile.

SP

Stelios Papadopoulos

Co-Founder & Independent Chair of the Board

Company leadership profile.

MM

Michael M. Morrissey

CEO, President & Director

Company leadership profile.

JL

Jack L. Wyszomierski

Independent Director

Company leadership profile.

JA

Julie Anne Smith

Independent Director

Company leadership profile.

TJ

Tomas J. Heyman

Independent Director

Company leadership profile.

GH

George H. Poste

Independent Director

Company leadership profile.

RL

Robert Lee Oliver

Independent Director

Company leadership profile.

DE

David Edward Johnson

Independent Director

Company leadership profile.

Expert coverage

1 expert evaluated Exelixis.

Orbitrum research

Experts evaluating Exelixis

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment